Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Olav Dalgard

Showing results (31-40 of 107) with videos related to

Pageof 11
Sort By:
Scandinavian Journal of Gastroenterology|June 13, 2026
Hepatitis C treatment uptake among incarcerated people in Norway, 2018-2019Eirik Opheim, Anette Fredriksen, Joakim Hauge, et al.
Trials|April 22, 2026
Antibiotic therapy in viral airway infections (ATHENIAN): study protocol for an open labeled randomized controlled pragmatic trial to evaluate the efficacy and safety of discontinuing antibiotic therapy in adult patients infected with respiratory virusesMagrit Jarlsdatter Hovind, Jan Erik Berdal, Jūratė Šaltytė Benth, et al.
Plos One|August 29, 2015
The Usefulness of Defining Rapid Virological Response by a Very Sensitive Assay (TMA) during Treatment of HCV Genotype 2/3 InfectionOlav Dalgard, Michelle Martinot-Peignoux, Hans Verbaan, et al.
Infectious Diseases (London, England)|October 5, 2023
Mortality and length of hospital stay after bloodstream infections caused by ESBL-producing compared to non-ESBL-producing <i>E. coli</i>Nina Handal, Jimmy Whitworth, Magnus Nakrem Lyngbakken, et al.
Hepatology (Baltimore, Md.)|March 5, 2011
IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infectionAmir Moghaddam, Espen Melum, Nils Reinton, et al.
Journal of Hepatology|September 20, 2016
HCV epidemiology in high-risk groups and the risk of reinfectionHåvard Midgard, Amanda Weir, Norah Palmateer, et al.
European Journal of Gastroenterology & Hepatology|May 16, 2012
Genetic variants at the ITPA locus protect against ribavirin-induced hemolytic anemia and dose reduction in an HCV G2/G3 cohortArne Nørgaard Eskesen, Espen Melum, Amir Moghaddam, et al.
Pharmacoeconomics|February 4, 2018
Economic Evaluation of Direct-Acting Antivirals for Hepatitis C in NorwayTorbjørn Wisløff, Richard White, Olav Dalgard, et al.
Infectious Diseases (London, England)|October 8, 2025
Treatment uptake among individuals notified with HCV infection 1990-2022 in SwedenCaroline Gahrton, Martin Kåberg, Charlotte Lybeck, et al.
Journal of Hepatology|October 8, 2013
Liver fibrosis progression at autopsy in injecting drug users infected by hepatitis C: a longitudinal long-term cohort studyKnut Boe Kielland, Gerd Jorunn Møller Delaveris, Sidsel Rogde, et al.
Pageof 11

Showing results (31-40 of 107) with videos related to

Sort By:
Pageof 11
Scandinavian Journal of Gastroenterology|June 13, 2026
Hepatitis C treatment uptake among incarcerated people in Norway, 2018-2019Eirik Opheim, Anette Fredriksen, Joakim Hauge, et al.
Trials|April 22, 2026
Antibiotic therapy in viral airway infections (ATHENIAN): study protocol for an open labeled randomized controlled pragmatic trial to evaluate the efficacy and safety of discontinuing antibiotic therapy in adult patients infected with respiratory virusesMagrit Jarlsdatter Hovind, Jan Erik Berdal, Jūratė Šaltytė Benth, et al.
Plos One|August 29, 2015
The Usefulness of Defining Rapid Virological Response by a Very Sensitive Assay (TMA) during Treatment of HCV Genotype 2/3 InfectionOlav Dalgard, Michelle Martinot-Peignoux, Hans Verbaan, et al.
Infectious Diseases (London, England)|October 5, 2023
Mortality and length of hospital stay after bloodstream infections caused by ESBL-producing compared to non-ESBL-producing <i>E. coli</i>Nina Handal, Jimmy Whitworth, Magnus Nakrem Lyngbakken, et al.
Hepatology (Baltimore, Md.)|March 5, 2011
IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infectionAmir Moghaddam, Espen Melum, Nils Reinton, et al.
Journal of Hepatology|September 20, 2016
HCV epidemiology in high-risk groups and the risk of reinfectionHåvard Midgard, Amanda Weir, Norah Palmateer, et al.
European Journal of Gastroenterology & Hepatology|May 16, 2012
Genetic variants at the ITPA locus protect against ribavirin-induced hemolytic anemia and dose reduction in an HCV G2/G3 cohortArne Nørgaard Eskesen, Espen Melum, Amir Moghaddam, et al.
Pharmacoeconomics|February 4, 2018
Economic Evaluation of Direct-Acting Antivirals for Hepatitis C in NorwayTorbjørn Wisløff, Richard White, Olav Dalgard, et al.
Infectious Diseases (London, England)|October 8, 2025
Treatment uptake among individuals notified with HCV infection 1990-2022 in SwedenCaroline Gahrton, Martin Kåberg, Charlotte Lybeck, et al.
Journal of Hepatology|October 8, 2013
Liver fibrosis progression at autopsy in injecting drug users infected by hepatitis C: a longitudinal long-term cohort studyKnut Boe Kielland, Gerd Jorunn Møller Delaveris, Sidsel Rogde, et al.
Pageof 11